Your Catalyst To a Lucrative Business
The global Idiopathic Thrombocytopenic Purpura Therapeutics Market is segmented according to products and regions . As per products , the classifications are TPO-RA ( thrombopoetin receptor agonist ), anti-D immunoglobulin , intravenous immunoglobulin ( IVIG ), anti-D immunoglobulins , corticosteroids , and others . Corticosteroids were valued over USD 125 million in 2013 and are the most widely preferred drug for treating ITP . Its high share in overall revenues can be attributed to its low price . TPO-RA can experience surging demand on account of commercialization of Avatrombopag . This can be attributed to the use of TPO-RA in splenectomized patients suffering relapses . Avatrombopag can act as a second line of defense due to its positive clinical trial results .
High response rates displayed by patients administered with Eltrombopag and Romiplostim can positively impact the TPO-RA segment till 2020 . Other therapeutic classes are interferon , immunosuppressant , and monoclonal antibodies ( mAbs ). mAbs such as Rituximab were used frequently in Europe till 2013 . However , patent expiry of the same has created scope for drug manufacturers to develop biosimilars .
North America , Europe , Asia Pacific , and RoW ( Rest of the World ) are regional segments of the worldwide ITP market . North America led the overall industry in 2013 owing to favorable government initiatives , rising ITP cases , and high research funding . Clinical trials based on combination therapy and drug developments are expected to spur regional demand over the forecast period . North America had a revenue share exceeding 40 % in 2013 .
Europe was the second largest market in 2013 propelled by high product penetration and favorable initiatives pertaining to its production . Asia Pacific is expected to prosper considerably over the next 6 years due to the untapped markets in India and China . Furthermore , sophisticated healthcare and government initiatives in Australia and Japan can contribute significantly to regional demand .
Notable players of the Idiopathic Thrombocytopenic Purpura Therapeutics Market are Grifols Biologicals Inc .; GlaxoSmithKline ( GSK ) Plc ; Amgen Inc .; and F . Hoffman-La Roche AG . These companies invest robustly in research and development to launch newer products in order to sustain their respective market shares .
GSK recently got approval for its trademark product “ Revolade™ ” by Health Canada , the department of the government of Canada that looks into national public health . This product is a capsule which needs to be taken orally to treat ITP . It can help boost production of blood platelets . Amgen Inc .’ s “ Nplate ” helps restore blood platelets in children . It can act as a viable alternative to treat severe bleeding concurrent with ITP . This drug had generated nearly USD 400 million in 2013 . Although Promacta and Nplate received approvals at the same time , the former is expected to dominate the market in the near future .
Browse Related Category Market Reports @ https :// www . hexaresearch . com / researchcategory / pharmaceuticals-industry
Follow Us :